OM Pharma is active at several Swiss medical congresses
August 16 th, 2006

OM Pharma is participating this summer in different specialised medical congresses where its qualified medical representatives attend to the doctors’ questions and other information requests in well-designed exhibition stands:

	at the Swiss Phlebology Society congress, Montreux, June 15-16, 2006, they focus on the mechanism of action and therapeutic benefit of the venoactive drug Doxium® in chronic venous diseases The physicians were particularly interested in the publication by Ramelet et al of a recent consensus symposium with international opinion leaders classifying Doxium® as an A level of recommendation for clinical use (i.e. characterized by randomized clinical trials with large sample sizes and metaanalyses combining homogenous results, see Clinical Hemorheology and Microcirculation, 33:309-19, 2005)
	at the Swiss Pediatric Society congress, Bern, June 22-23, 2006 and the Swiss French-Speaking Study Group of Ambulatory Pediatrics, Lausanne, September 14, 2006, they present the latest information on the efficacy and safety of Broncho-Vaxom® in children
	at the Swiss Society of General Medicine, Basel, September 21-23 2006, they emphasize the lead role of Broncho-Vaxom® in patients suffering from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary diseases.